Latest Agh News

Althea Group Holdings reported a resilient September quarter with $5.4 million in receipts despite a major strike in British Columbia, bolstered by a $2.53 million capital raise and expansion in the US THC beverage market.

Althea Group Holdings has secured $2.55 million through a share placement to fuel expansion of its Canadian THC beverage manufacturing arm, Peak Processing, as it targets growth in both Canadian and US markets.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Althea Group Holdings reported significant cash outflows in Q2 2025 due to one-off costs but anticipates operational improvements and revenue growth from its North American business units.

Althea Group Holdings reported significant cash outflows in Q2 2025 due to one-off costs but anticipates operational improvements and revenue growth from its North American business units.

Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.

Althea Group Holdings has agreed to sell its pharmaceutical assets to Tasmanian Botanics, enabling a strategic pivot towards the booming North American THC-infused beverage market.

Althea Group Holdings reported $5.02 million in Q3 FY25 receipts, driven by strong growth at Peak Canada and the launch of Peak USA, while its pharmaceutical cannabis division faces steep revenue declines prompting strategic review.

Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Althea Group Holdings Limited has had its trading suspension lifted following a Federal Court ruling related to cleansing notice lodgement failures, marking a key regulatory milestone for the pharmaceutical company.